Principal Investigators announced global availability of its online platform designed specifically to connect Medical Doctors with Pharma and R&D companies involved in clinical studies
Principal Investigators® (www.principalinvestigators.com) announced the global availability of its online platform designed specifically to connect Medical Doctors with Pharma and R&D companies involved in clinical studies. With principalinvestigators.com medical doctors can create a profile and start referring their patients and increase their ability to start a new clinical trial at their site. It allows Pharma & CRO companies to locate investigators from all over the globe and carry out feasibility all in one place. Investigators also can monitor offers, apply to trials within their area of expertise and gain new business.
Read the full release here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.